MedPlus Health Services Ltd
NSE:MEDPLUS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
602.95
807.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
MedPlus Health Services Ltd
Earnings Call Analysis
Q3-2024 Analysis
MedPlus Health Services Ltd
The launch of the company's private label products has seen a hearty welcome in Telangana, marking a successful first move. The company is now experiencing a steady climb in acceptance of these products, post their nationwide release in late October. While addressing misconceptions around generics, the company outlined its strategy in providing significant discounts ranging from 50% to 80%, which has stimulated early adopters to switch. These efforts extend beyond just the stores with a push through media, influencers and various testimonials to further enlighten consumers and drive conversions.
The private label rollout has been clarified to have reached all states and stores, correcting any previous misconceptions about its extent. This expansion strategy is aimed at improving margins, which are anticipated to increase from around 13% to 22%-23% as the private label replaces branded products. Even though there might be an initial loss in margins from the replacement of their current private label, Wynclark, the long-term perspective foresees this as an overall gain for the company.
The company's primary goal with their MedPlus brand is to magnetize new customers, aiding in top line growth rather than solely focusing on margin expansion. By attracting consumers from competing outlets, including smaller mom-and-pop pharmacies and other organized stores, they aim to significantly increase their current market share beyond the retained 15%-20% in the cities where they currently have a strong presence. These efforts are expected not only to convert existing customers but also to capture an additional 10%-20% from the remaining market base, prioritizing revenue growth over immediate margin benefits.
With an increase in sales volume, store-level EBITDA margins for mature stores are expected to rise. The company provided a specific example: a 10% sales increase would carry an EBITDA margin improvement of 200 basis points. This improvement is due to heightened sales at existing stores as the product mix shifts more towards the higher-margin private label offerings. Subsequently, the focus is on leveraging the MedPlus brand's price and quality narrative to drive not just a shift within its customer base but also to attract new customers, thereby amplifying the long-term profitability of mature stores.
You don't have any saved screeners yet
Ladies and gentlemen, good evening, and a warm welcome to the MedPlus Health Services Limited Q3 FY '24 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Prasad Reddy from MedPlus. Thank you, and over to you, Mr. Reddy.
Thank you, Mitchell. Good evening, everyone. On behalf of MedPlus, it's my utmost pleasure to welcome you all to the MedPlus Q3 FY '24 Earnings Conference Call to discuss the financial results of MedPlus for the third quarter of financial year 2024, which were announced on 2nd February 2024.
We have with us today the senior management team represented by Mr. Madhukar Reddy Gangadi, Chief Executive Officer and Managing Director; Mr. Sujit Mahato, CFO; and Mr. Chetan Dikshit, CSO.
Before we begin, I would like to mention that some of the statements made in today's discussion may be forward-looking in nature and may involve risks and uncertainties. Please note the disclaimer mentioning these risks and uncertainties are on Slide 1 of the investor presentation shared with all of you earlier. Documents relating to our financial performance was circulated earlier, and these have also been posted on our corporate website. I would now hand over the call to Sujit, the CFO. Thank you, and over to you, Sujit.
Thank you, Prasad, and good evening, everyone, on this call. We are pleased to share that as of December 31st, we have been serving community in over 600 cities across 10 states, including the 3 new states of Madhya Pradesh, Chhattisgarh and Kerala through our network of 4,233 pharmacy stores. Additionally, in Hyderabad, MedPlus operates 4 full-service diagnostic centers, 8 level 2 centers and over 120 collection centers offering essential diagnostic services at affordable rates.
Let me cover the network in terms of openings and closures of our outlets. As confirmed during the last quarter, we have taken a thoughtful approach towards store expansion, prioritizing scale-up of MedPlus-branded pharma and nonpharma products and also maintaining a balance between overall growth and profitability.
Over the past 12 months, we have added a net total of 676 stores. On a gross basis, this was 758 stores, with 164 stores opened during Q3 alone. Most of the new stores were opened in Tamil Nadu and Telangana with 55 and 24 stores, respectively.
This strategic focus of growth reflects our commitment to meet the evolving needs of our community while maintaining a focus on sustainability and financial health. We expect the new store openings for the fiscal year 2024 to be around 600 stores.
In the third quarter, 59% of our store openings were in Tier 2 cities and beyond, underscoring our strategic emphasis on these markets. Presently, out of our 4,233 stores 1,908 stores, representing 45%, are situated in Tier 2 cities and beyond. We acknowledge the growth potential inherent in these markets.
Throughout Q3, there were 20 store closures. Taking into account both openings and closures, we achieved a net addition of 144 stores during the current quarter, a notable increase compared to the 114 added in the previous Q2 quarter.
In terms of the network age. Approximately 18% of our scores are in the first year of operation, around 27% of our stores are in the second year of operation and the remaining 55% of our stores have been operational for 2 years or more. It is noteworthy that all stores in the less than 2 years age bracket are still in their ramp-up phase. From a financial standpoint, they continue to exert a negative impact on our operating EBITDA.
However, as these stores mature, we anticipate a positive contribution to our profitability. We closely monitor the timeframe for our new stores to reach breakeven. For stores opened between January 2023 and June '23, approximately 59% of them achieved breakeven within 6 months of their operations.
As of [indiscernible] all stores combined reach breakeven in just 4 months. In terms of the store size as at the end of the quarter, our network has grown to 4,233 stores, covering 2.2 million square feet compared to 3,557 stores over 1.9 million square feet as of the end of December '22.
The average store size was 535 square feet. To give you a sense of spread in store sizes, we had 3,082 stores less than 600 square feet and 1,151 stores that are greater than 600 square feet.
In terms of revenue mix, with our expanded scale, we are strategically positioned to increase our revenue share from our private label products. Our private label range is crafted to provide customers with high-quality products at competitive prices.
Presently, MedPlus offers over 1,000 carefully selected SKUs spanning across pharmaceutical and nonpharmaceutical category. Private label sales currently constitute 14.5% of our total net revenue. However, our growing presence in Tier 2 cities and beyond is significantly impacting our revenue mix. Sales from these markets comprise 35% of our pharmacy revenue in the current quarter, marginal increase from 33% in the same period last year.
I'm pleased to provide an update on the impact of the launch of MedPlus-branded products in Telangana state. In quarter 1 FY '24, prior to the launch, the share of private label pharma stood at 6.61% of the total GMV in Telangana. However, following the launch and in quarter 3 FY '24, the gross merchandising value notably increased to 15.03% of the total GMV in Telangana.
Following the promising results observed in Telangana, the company initiated the launch of MedPlus branded products in other states starting October '23 onwards. Prior to the introduction of MedPlus-branded pharma products, sales of private label pharma products accounted for 8% of the gross merchandise value in quarter 2 of FY '24.
However, subsequent to the launch and throughout the reported period, the private label share of GMV surged to 11.2%. The increase in private label GMV indicates the positive reception from customers and validate our commitment to delivering high-quality products under the MedPlus-brand umbrella.
Now coming to the financial numbers. On our quarter performance, our consolidated revenue was INR 14,415 million with a growth of 21.1% year-on-year and 2.3% quarter-on-quarter. Our consolidated operating EBITDA stood at INR 466 million, representing 3.2%. Around 99% of our revenue is from our pharmacy operations.
The pharmacy operating EBITDA is INR 505 million, representing 3.6%. In terms of our store performance, I would like to update on our stores older than 12 months. Revenue from these stores in quarter 3 was INR 12,953 million or 91% of pharmacy revenue.
These stores had a store level EBITDA margin of 9.6%. The store level operating ROCE of these stores stood at 52.5%. A word here on the store level EBITDA margin by age. While stores greater than 12 months had a margin of 9.6%, this was 10.1% for stores greater than 24 months and 7.2% for stores in the 13 to 24 months age bracket.
If we allocated the nonstore related costs, then the operating EBITDA of stores greater than 12 months to the INR 588 million, which translates to a margin of 4.5%.
[ Quick ] numbers. Diagnostic revenue has grown to INR 196 million in Q3 '24 compared to INR 97 million in Q3 of FY '23, which is primarily due to launch of the new centers across Hyderabad.
Diagnostics segment recorded an operating EBITDA loss of INR 34 million compared to a loss of INR 33 million in quarter 3 of fiscal year '23. Our net working capital for quarter 3 was 66 days. The inventory in our warehouse was 38 days.
As you are aware, because of the same trajectory of new stores, their inventory turnover is lower in the first year. In Q3, the inventory level of our first year store was INR 111 million. In comparison for our stores older than 12 months, the inventory was 42 days.
Now I request Chetan to share an update on our diagnostic business. Over to you, Chetan.
Thank you, Sujit, and good afternoon, everyone. As you know, Q3 is a seasonally weak quarter for Diagnostics in great part due to the festival and holiday season. However, we have 8% quarter-on-quarter growth in Q3. In October, we sold 405 gross clients per day. In November and December, this was 369 and 357, respectively.
As on 30th September, we had 117,000 active plans and 207,000 underlying lives. As of 31 December, we had 127,000 active plans and 228,000 underlying lives. Our current observed on-time renewal rate was 19% in Q3 versus 15% in Q2.
That concludes our update for the quarter. I request the host to open the line for questions.
[Operator Instructions] The first question is from the line of Aashita Jain from Nuvama.
My first question is on your store opening guidance. I think for this year, your store down to 600. What is the store opening guidance for the next 2 to 3 years or 3 years for FY '25? Can you give color on that?
Sure. Thanks, Aashita. So as Sujit said earlier in this call, we have focused primarily on increasing the overall private label, both in pharma and nonpharma. That's going to be our focus for the first 1 or 2 quarters this year also. We've just introduced over 600 products. And even as the product line is expanding, we are also making sure that products are available across the entire network and all.
And we're also ensuring that our employees are fully trained and are able to sell and everything else. So as I said, the primary focus is going to be on this. We will most likely end up doing only around 600 to 700 stores the next year, the coming year, too. But we will keep you guys updated as soon as [indiscernible] which is finalized.
Sir, you just spoke about last few quarters about entry into the newer market. What's the update on that?
It is still early going for the 3 states, one is Kerala, Chhattisgarh and Madhya Pradesh, but we are, I would say, pretty encouraged by the response in all these places. We will put up a small -- a very small working kind of warehouse to make sure that we are able to service all our stores properly and all.
But in general, both Madhya Pradesh and Chhattisgarh are doing well. We expect to grow faster than that. There are -- I would say, the growing is a little bit slower in Kerala for us, but we continue to expand in that state also.
Any particular reason for this Kerala -- slower uptick in Kerala?
So see, a lot of the initial store opening depends on the regulator over there. There are some regulators who are slightly more sticky about every single detail and in some states, it is not as much. It is a state-wise thing. So it is a slow growing in the beginning stages, I would think. But yes, that's about it is. Otherwise, it's not an issue. The market itself is pretty good in Kerala.
Understood. And I think phenomenal job on the private label side, now we're close to 14.4% pharmacy percent [indiscernible] this number would settle in the next year, given our initiatives on the MedPlus value cases.
It's really difficult to say. We are very encouraged with the way the initial 2 states have responded with the initial 2 regions where we started in June have responded. And also under the early [ listing out there ] in the other states, it is following the same path.
Just on the pharma side alone. I think given that 80% of our sales comes from pharma right now, and we will be able to hit or at least we'll be able to, I would say, have such for at least 60% of the entire inventory, which is 70% at least of the medicines. I think for us to get to 20% will not be very tough on the pharma side over the next 1 year.
[Operator Instructions] The next question is from the line of on Saion Mukherjee from Nomura.
Sir, on the private level, the MedPlus brand. So I mean what you see at a GMV level, how the ratio has moved? If you get your share at an overall company level like how much it was before, let's say, when you launched in first quarter and now?
Yes, I'll take that, and thank you for the question. In quarter 2, in terms of the GMV, the private label Pharma was 8.96% overall. And end of quarter 3, the same percentage on the same basis of GMV reflects at 11.78% [indiscernible] fold.
So this is for the overall, entire pharmacy...
Overall. Only for the private label pharma.
Understood. Okay. And the other question I wanted to check with you is that you have provided stores less than 12 months revenue split. How has been the revenue growth for stores, which are, let's say, more than 2 years old? I mean, is that growth very slow? I mean, is that a right assessment that it's in single digits?
In fact close to the inflation number. If we get all stores put up to FY '21 end, it is inflation-plus.
Okay. But generally, the pharma market growth is around 9%, 10%, right? And if there is price increase that is also there in pharma. So I was wondering why this number is a bit lower? Is there sort of a destabilization with the new store opening? How do you sort of read this [ number ].
Yes. So Saion, while definitely there is some price inflation and unfortunately the DPCO rules which kick in once every while, also reduce the prices a little bit. So there's also that impact. For us, I expect that the growth will be slightly over inflation as we go forward.
There may be some cannibalization in some existing states, but I don't really expect that to [ meet ] the sales any more than it should. For us, the other main reason could be also this. We are not really -- except for places where we're reporting the private label, we are not taking the GMV route to actually explain the sales growth.
So in some of those cases where private label medicines have actually taken off, you would see a slight dip in the pipeline because of the lower value at which we sell the discounted private label products, the new pharma private label products.
Right. Sir, is it possible to share the growth numbers on a like-to-like basis at the GMV level? Is that possible to -- like you reported 21% growth, how much would have been [indiscernible].
Sujit, do you want to take that?
Madhukar, I'll take that Saion, our reporting what we have done is we've benchmarked it to peers. But we take your feedback on those and see if there's more disclosure that we can give going forward.
Okay. And finally, are there any changes in the discounting in your normal branded products due to competition and behavior of online players? Any changes that you have witnessed in the recent past?
We have not increased the discounts anywhere. And if your question was, if the competition is actually coming down, are you taking by decreasing it? No, not as of now.
We'll take the next question from the line of Gaurav Nigam from Tunga Investments.
Sir, first question was on, I was looking at your presentation, you used to give this private label number of pharma SKUs. That number from Q2 to Q3 presentation is dropped from almost 1,100 to 783. Just wondering, is this a correct number to look at? And what's the reason if this is correct?
We will have to come back to you. I don't think we have really decreased the overall number. If anything, given that we have been continually increasing the pharma private label and also [indiscernible] the overall number of products. Sujit, do you want to add anything else [indiscernible].
I will come back in a while.
Understood, sir. Another question was on, can you provide the average level of pharma discounts that was there in Q3? And has it -- quarter-on-quarter, has it increased or reduced, any sense of direction?
Pharma discounts on branded products has not really increased significantly. There may be a little bit of increase in 1 state, West Bengal, where the earlier hurdle was -- after the earlier hurdle we used to give a 10% discount, we moved it to 15%, but that was at least 2 to 3 quarters ago. Otherwise, I see no reason for any increase in discount.
If as a blended this thing is coming out at slightly higher discount, it could be because of our private label products. Our private label products, the new ones [ sell ] at an average of 50%. So if you combine the entire pharma products, then that could increase the discount. But I think if you look at purely the branded ones, there should be no increase or there should be very little increase.
Understood, sir. And sir, what is the guidance for Diagnostics CapEx in FY '24 and '25, sir?
Do you want to take that Sujit or Chetan?
Yes, sure. I can take it. Apart from maintenance level CapEx, we don't have anything really planned in terms of big machines or new centers. If there is a change in these, we will definitely update you.
In FY '25, sir, as well, you're saying?
Yes. For the foreseeable horizon, our CapEx program has been rolled out. In some of the centers, we may have minor CapEx maybe an additional ultrasound, ambulance. So which is why I cannot spoke about it like maintenance CapEx. But there is no plan on the cards for new centers or new cities or new big machines. We will update as and when anything like that is on the cards.
Understood, sir. And sir, just a last question. Is there any update on the QIP? I think you have taken a shareholder approval. So just wondering if there is anything in the plan going forward.
Thank you for asking that question. We have -- we maintain our stance that what we have taken was shareholder enabling provision just to keep that optionality and that is for a full duration of 12 months. As and when the circumstances require us to raise additional funds, we will then have the option of both looking at equity and debt. As of now, it is an enabling provision, and there is no action expected on it in the near-term.
We'll take the next question from the line of Kunal Randeria from Axis Capital.
Madhukar, your private label sales contribution on the pharma side has actually gone down on a year-on-year basis, right? But your GMV has gone up, I believe, so does that mean [indiscernible] MHS had a lot less discount than made by MedPlus brand?
Yes. So earlier Wynclark and even a little bit of the [indiscernible] indexes we sold were sold at the same price as branded products. Since then, we have decided to virtually go with a store generic thing, promote MedPlus brand and give it the full discount. So while a response to this has been very good, there has also been a little bit of cannibalization of our original Wynclark brand. And so in some places, that has come down a little bit. And so overall margin will have come down because of that.
Okay. So do you still sell under Wynclark.
Sorry?
Do you still sell under the Wynclark brand or have you stopped it?
No, no, we do, we do. So we will continue that at least in the acute kind of therapies and all. In Telangana, the entire state of Telangana, we have reduced the price of Wynclark to the level of the MedPlus brand. So we sell it at the same price, all the products have been sold at the same time. But in the states in which we have started after this, in the rest of the country in the southern states, Wynclark continues to sell at the old price because some of the chronic -- for some of the chronic therapies, the sales has come down. Most likely will come down to next to nothing as they were in a while, we'll let that happen for a period of time. But we will continue to actually sell the Wynclark private label at the full price for acute therapies.
The idea is that for those who are not very price sensitive, those who are not members of the MedPlus discount plan and all and they would need the -- and those who are seeking early convenience from them, we will get the full price. Otherwise, in the [indiscernible] price-sensitive will get the MedPlus brand at the full discount.
Got it. And just 1 last 1 on this. So this is more like your -- it's been a few months since a launch made by MedPlus. Let's say, as it gets bigger and people recognize the brand, do you plan to reduce discounting slightly, let's say, from 70% to a 60% or something like that?
So today, our overall discount is at around 60%. We would say 50% to 80%, but the average falls at 60%. That is something we will see as we go forward, depending on how the market is evolved. Our primary thing right now concerns to grab market share and increase the top line. Once it is fully established, people understand the quality of the product and people are buying MedPlus -- are asking for [indiscernible] coming and buying it, when we could always play around either with the top line, either with the MRP price increase it slightly or perhaps decrease the discount to a slightly lower number.
But that is not something which we are going to decide right now.
All right. Just more if I can. Have you introduced it across the states or is it just Telangana at the moment?
No, it is across all the 7 states right now. As I said, only in Telangana, we have killed our old private label. Everything is now available at the new MedPlus private label brand rate -- but in the other states, both co-exist.
The next question is from the line of Harith Ahamed from Avendus Spark.
I joined the call a bit late, so my apologies if this was asked before. So my first one is on store additions. I see that we are tracking around 400 stores added year-to-date FY '24. So I remember that previously, we had guided for roughly 1,000 stores addition, 800-plus. So what would be the updated number for FY '24? And is there a revision in the guidance for FY '25 and beyond in terms of net additions?
Sure. The number of stores, the gross additions this year will be close to 600, around the 600 mark, the net additions may be slightly lower. And for the coming year though, the number could be around the same number. The focus this year is going to be on private label. We want to make sure that we get us to the 20% kind of mark on the pharma side. So that's going to be the thing -- both by increasing the range, increasing the awareness and also increasing the education level of our own employees in being able to sell this product.
So based on your experience so far on the MedPlus-branded private label side, can you share some of the lessons or challenges that you've encountered in this foray? Is it on the sourcing side or is it in terms of getting subscribers? And if you can comment on the willingness that you're seeing among patients to switch from the brand to the private label, so if you could share some of the takeaways on these areas, that would be helpful.
Sure. So you have seen a pretty good response to our products in Telangana where we launched it first. The results from this are only a quarter will actually we started only in the middle of October or late October in the rest of the country. So the numbers are still not there. But in Telangana, we have seen a very good response.
What I think is that the early adopters, people are buying the product but all the products available in the market are generic only. And MedPlus is able to give a very good price only because it does not have any marketing or distribution costs. So people are getting that. So some of early adopters have come on board.
We think as we go forward -- but there still remain some questions. I think we have our work cut out in trying to educate the customer. The common question we encountered is this: whenever our guys have gone and said 50% to 80% discount on our brands, they have said customers have come back and said is this a generic product?
So we are taking the time to explain that all the products in the country are generic. There's really no difference. It's all the same product in the end. The only way you can differentiate one from the other is on the quality of its make. So we are countering that using several different explanations out there. And we are seeing a lot of people converting once that happens.
So this will happen not just through our stores, but also through media, influencers and all types of other testimonials and all. Again, to come back to your question, how is the response? Pretty good. The early adopters are on board. People like this something they're saving a lot of money. We're seeing a steady increase.
But I think if you want to hit the next, let's say, level of growth, we'll have to answer some of these questions, which we are now in that process today.
Okay. Just a clarification, Madhukar, you mentioned that you've launched it across all the states that you operate in, but in select stores. So I was just wondering that from an operations standpoint, would be easier to launch it across all the stores in a certain market versus launching it in select stores?
No, I may have communicated it wrongly. We have actually launched it across all states all stores.
All states, all stores.
I don't know why it came out like that. Yes, yes, now it is all states, all stores.
And last one, I didn't get 1 number that you shared previously, the store level margins for stores of more than 24 months of maturity?
Yes, Sujit, do you want to take that?
Yes. It's around 10.1, Harith.
The next question is from the line of Madhav Marda from Fidelity International.
My first question basically was that as we target this 20% private label mix in the pharma portfolio, how do you see the gross margins for the company trending, say, in the next -- I think you said that you can hit the 20% mark over the next year-or-so. So if you look a couple of years out once we have that Mark, how do you see the gross margin profile? Like I think we're trending at about 21.5%, 22%. How do you see this changing for the company?
So Madhav, we'll try and give you a guidance as we go forward on that. So it's going to be a function of 2 things. One, as we replace the branded product, we will see an increase of around 0.1 or 14%, overall...
Sorry, I didn't get you, you said half...
No, no. As we replace the branded product, right, on the branded product, post-GST, post everything and all, we probably get around 13% overall margin and this one basically gets us around 22% to 23%. So there'll be that increase as we replace that. But in the initial phase, though, we may end up replacing some of our own private label, which is Wynclark. While we continue to basically run both of those, I think the consumers who are buying chronic product, the medicines for chronic ailments and who are buying the Wynclark brand on that, may switch over to MedPlus brand.
And there, for every one person, we will probably end up losing around 0.3%. So in the conversion -- if you convert maybe 2% or 3% out there, you'll probably end up losing 1% gross margin on the Wynclark side. But after that, it will all be a gain.
Okay. No, sir, you're saying Wynclark...
So Madhav, sorry to interrupt there. See, our goal in trying to actually get this MedPlus brand popular and get the word out to everyone about the quality and the pricing of that is not to convert the existing customers into the MedPlus brand, but we actually get customers to increase their top line by bringing in customers from the other mom-and-pop and other organized stores.
We are seeing a lot of people actually doing that. So we expect the benefit to us is going to be more on the top line than on actual margin side.
Okay. Okay. Understood. So -- got it. So would that mean that if earlier, like you said the store level EBITDA margin for 24 months plus stores were actually 10.1%. Essentially, what we're saying is that there is gross margin and then there's EBITDA margin. So in your view, if we get higher volumes at the existing stores, would you have a view on where the store level margins for the mature stores could move? Because I guess that's what we are finally trying to target?
Sure, sir. So for us, I mean just -- if we were to increase our sales by, let us say, 10%, over the current level, right, the average store, let's say, is doing around INR 15 lakh out there, if you were to increase the top line without really changing anything else by 1%, that's -- that will increase sale by INR 1.5 lakhs. The margin will be INR 30,000 extra. And that would actually increase the overall EBITDA by 2%.
Okay. Okay. So basically, the sort of older version versus the new version of stores, you could get 200 basis points higher margin, as this mix of private label goes up because we'll sell more basically at the same stores, right?
Sir, the idea is to be able to sell more because if it was purely for margin accretion, then we will just continue and the old private label and [ just continue ] that. What we feel is introducing a store generic concept for the first time in India, getting people to -- see, our ability to convert a normal customer into the Wynclark customer for a higher margin is only so much given that our pricing was not any lesser than the other brands.
Now when we talk about it and when we tell people about the MedPlus brand and its quality and we also talk about the price advantage to them, we see a lot more people, a lot more receptors. So, a, conversion of our existing customers; but b, more importantly, we have only about 15% to 20% of any other markets in this city, even though we are really big.
We feel the balance 80%, do you feel we'll be able to win over at least 10% to 20% of the balance 80% who are not shopping with us based on the price. And that's what we're looking for. Yes.
The next question is from the line of Sayantan Maji from UBS Group.
My first question is on the portfolio of private labels. How much of it -- sir, how much of the current pharma sales are these private label seeing? So I remember a number that you had given earlier was somewhere around 55%. So has it increased now, now that we have launched it nationally? Or is it still somewhere in that range?
No, it has increased slightly. So earlier when we talked about it, it was 80% of our overall sales comes from medicines and 55% of that -- for 55% of that we had a substitute. So on the overall scale, we had substitute for 44%. Now that 55%, I think, has now moved to around 60% or 62%, but we have also placed an order for a lot more medicine. So I expect that it will give you up to 70% as we go forward.
Okay. So if I say, let's say, 70% of 80%, which is, say, 55%, so out of this 50%, 55%, you are expecting a 20% share of pharma private label or is it on the total sales?
No, we are expecting on the total thing. See, on this 56%, the 20% is already there almost because even leaving aside Telangana, the rest of the country is at 11.2%. So out of the 56%, 20% would be only 11.2%, right? So we already have that. And in Telangana it is actually 14%. So the number is slightly higher. So when I'm talking 20%, I'm talking 20% on the overall number, so which will actually become 20% and 56%.
Okay. Okay. So this is basically the share of GMV, not the net revenues?
Yes.
Okay. Got it. And also, I think in the opening remarks, you had mentioned that the share of pharma private labels has increased from 8% to 11.2%. And later in the call, you said 8.96% to 11.78%. So is it the difference between the timing? Or is it -- can you just explain like where is the difference coming from?
Sure. Sujit, do you want to take that?
Yes. We had the first number, 6.61% to 15% was an update on only Telangana, which we have launched end of June. And the second one, 8%, going up to 11.2% is all states put together, excluding Telangana. It's the [ only once ] during October, and that's relevant to the quarter.
Okay. Understood. Okay. That's clear. And my second question is on Diagnostics. So in Diagnostics, we are ramping up in Hyderabad. So -- and I remember you're saying that it is a pilot. And once the pilot is successful, you will expand to other cities. So when do we -- when -- at what point will the decision be taken to expand into other cities based on the results of the pilot in Hyderabad.
Sure. Chetan, I'll take this. So yes, no, this continues to be a pilot still. We today are at around 120,000 subscribers serving roughly around 220,000 people out there. The goal is for us to get to at least 200,000 number before we can take a call on expanding in the current situation.
We'll take the next question from the line of Tanmay Gandhi from Investec.
Sir, firstly, if you can clarify the private label pharma sales on the right. So is it possible to split it between MedPlus branded and the normal private labels which we used to have even earlier on a net revenue basis?
Sure. We'll see if you can do that. But for Telangana, that is Hyderabad and rest of Telangana state, all of them are lumped into 1 category right now. To the customer, it doesn't matter because he's getting the same price. To us also, it doesn't matter. So we're just not differentiating them on there, but we should be able to give you the actual split.
In the others [ state ] of item out of the 11.6% or 11.7%, I think around 5% is probably the old Wynclark. I'm not sure, Sujit, do you -- if you have the right numbers, you can just go ahead.
So it's around 11.2% on a net revenue basis, the old and the new put together.
No, sir, actually. No, no, sir, actually, I want it on a net revenue business which we report, right? So I want to split off...
I mentioned it is on a net revenue basis. I'm mentioning on a net revenue basis. But both the old as well as the new put together, as Madhukar explained that in the state of Telangana, we have not differentiated between the erstwhile model and the current MedPlus brand. And therefore, on a total basis, this is around 11.2% net.
Okay. Got it. Okay. And secondly, now that we are -- the pace of store addition has come down. So how should we look at the corporate level operating margins? So should we see a meaningful uptick or you plan to invest in some other initiatives like Diagnostics or the MedPlus-branded generics which you have launched?
Okay. See, on the Diagnostics, as we said earlier, we're not going to be doing any other investments. We want to -- I think we are fully invested, except for some small maintenance CapEx, as Chetan said earlier. We will be wait to see how it is shaping up. We are doing well on the B2B side. We also want to see some traction on the B2B and post that we will figure out how to actually expand either on investments in the same place or in going to new cities.
On the private label side, there is no significant investment for us. The cost of the medicines is not very high, and it is just replacing one part from the other that's all. So I think the benefit of adding lesser stores, should be, I would say, more on allowing us to focus on the private label and possibly on the profitability also as we go forward.
Sure. So sir, if we look at your operating EBITDA bridge that you provide, right, what are the various drags on the reported numbers. So I think the biggest drag comes from the new store additions and given that now we have a bigger base and obviously, the addition will also be lower in FY '25. So is it fair to assume that there will be a significant uptick in EBITDA margins? Or it will be steady expansion on this?
No please. Again for now it is going to be a steady growth only in that. We will see how the private label and all the top line and all go up. I know the cost will be slightly lower, but I don't think that will -- I think the bigger driver for us is -- are the first 2 which is top line and private label component.
[indiscernible] Tanmay, I think you have the modeling inputs over the last many quarters. The reason why you heard Madhukar say what he said was because we do see the new private label having a fairly large opportunity. And we may have additional nonstore operating costs like marketing, et cetera, which is what Madhukar said, what we said.
Sorry, I lost you Chetan, sir, but my question was that given that we are right now just giving our store addition guidance, should we assume good uptick in margins because as Madhukar had said that we are not spending a lot on private label side? Sorry, I missed you, I do [indiscernible] this is the question.
Absolutely. We couldn't comprehend what he said at least at our end it was quite garbled.
Mr. Gandhi, I would request you to kindly use your handset to ask questions, please.
Yes, is there any better?
Yes.
Sir, so my question was that, so because we are reducing our store additions for the next year, and obviously, now we have a better base as well, right, larger base, so should we assume a significant uptick given that we are not spending much on marketing as Madhukar has said, right? So I just wanted to clarify that what are the various drags on the margins?
Because if we are lowering our store additions, then ideally there should be -- the gap between 12-month-plus stores margins and the reported margins for -- at the company level should be [indiscernible] over, right?
No, what you're saying is right, Tanmay. Logically, if we have lesser new stores, yes, definitely. But for us, the drag of that was never very big anyway. We will continue to report stores, which have more than 1 year old and all. I think it should definitely be slightly better as we go forward.
The next question is from the line of Neelam Punjabi from Perpetuity Ventures.
My question is on the Diagnostics business. So if I look at the latest quarter, we have already reached an INR 80 crores annualized run rate for the diagnostic business. However, we are still supporting our losses segmentally. So by when can we turn profit in our Diagnostic franchise?
Yes, sure. Chetan, do you want to take that?
Yes, sure. I can take the first crack at it. Neelam, the Diagnostics business also has a similar structure like pharmacy in the sense that a lot of operating costs sit both at the center and outside the centers. So because the Diagnostics business has costs which are at the HO level, which are currently not diversified across many cities, the segment continues to be dragged by those costs.
The improvement in the performance of the centers naturally, will make up for some of that. And we do expect to report the segment as profitable. But what we haven't disclosed so far is the center level profitability for diagnostics as we do in pharmacy which is why if you can just keep that framework in mind that what's ramping up is the revenue and the profitability of the diagnostic center.
But the HO level costs, which are actually at a multicity level that [indiscernible], whether it is procurement or absorb various lines of sub business, that continues to be a drag because our current operations are limited to Hyderabad.
Okay. But however, then can you help us understand what's the center level EBITDA margin, at least like for the mature center, the oldest -- first the Gachibowli center, if that will be helpful for us to understand then?
Sure Neelam. If you allow us, we'll do that in the next quarter.
Sure. Okay. And 1 clarification I needed. For the private label for our pharmacy business, we gave a target of about 20%, right? So is that on the net revenue or GMV basis?
Sujit?
Yes. I think we are talking on a GMV basis, please.
We'll take the next question from the line of Lokesh Manik from Vallum Capital.
I have just 1 question from my end is being on the store addition in this quarter is net addition of 144 stores, but the rent expense is flat at INR 53 crores. So can you please help me reconcile this [indiscernible] flat?
Yes, I'll take that. So if you observed last year for the similar period, over the period, we opened around 1,100 outlets at various points in time during the year. And in the current year, during the 9 months, we have opened 400-plus outlets. So that is the full impact taking care of the timing issue. But for that, there is no -- but for that, I would say we have the 5% to 7% annual contract base increase. So that's the major reason for the variance in the rental expense.
Okay. But for this quarter, we should have expected a higher rent expense I mean because we've in line for the [indiscernible] which are not there in the last quarter. So quarter-to-quarter, it's flat Q2, Q3 it's INR 53 crores.
Yes?
Yes, Q2, Q3 is flat at INR 53 crores, and there is an increase in store addition of 144 stores. I'm just trying to understand how the rent expense is...
Yes. It's in line with the contracts which we have entered [indiscernible] and there is no exceptions in those numbers.
Ladies and gentlemen, that was the last question for today. I would now like to hand the conference over to the management for closing comments. Over to you, sir.
I thank all participants on this call for your interest in the MedPlus journey. Our Investor Relations team can be contacted at ir@medplusindia.com. Thank you, and have a great day.
Thank you, members of the management. Ladies and gentlemen, on behalf of MedPlus Health Services, that concludes this conference call. We thank you for joining us, and you may now disconnect your lines. Thank you.